Linomide in relapsing and secondary progressive MS: Part II: MRI results

Neurology

Volumn 54, Issue 9, 2000, Pages 1734-1741

  Wolinsky, Jerry S ^a   Narayana, P A ^a   Noseworthy, J H ^b   Lublin, F D ^c   Whitaker, J N ^d   Linde, A ^e   Gjorstrup P ^e   Sullivan, H C ^e  

^a UNIVERSITY OF TEXAS   (United States)

^b MAYO CLINIC   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e PFIZER INC   (United States)

Author keywords

Linomide; MRI; MS; Treatment

Indexed keywords

ROQUINIMEX;

ARTICLE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0034624943     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.9.1734     Document Type: Article

References (24)

1. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 1997;120:865-916.
2. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med 1997;337:1604-1611.
3. Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: Part I. Trial design and clinical results. Neurology 2000;54:1726-1733.
4. Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996;47:895-900.
5. Hohol M, Guttmann C, Olek M, et al. Roquinimex (linomide) treatment in secondary progressive and relapsing remitting multiple sclerosis: results from 48 week randomized, double-blind, placebo-controlled pilot studies. Neurology 1997;48 (suppl):A174. Abstract.
6. Karussis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996;47:341-346.
7. Bedell BJ, Narayana PA, Wolinsky JS. A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med 1997;37:94-102.
8. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
9. Narayana PA, Borthakur A. Effect of radiofrequency inhomogeneity correction on the reproducibility of intracranial volumes using MR image data. Mag Reson Med 1995;33:396-400.
10. Wolinsky JS, Narayana PA, the MRI-AC (Houston, TX) for the North American Linomide Trialists. Pre-randomization characteristics of relapsing and secondary progressive multiple sclerosis subjects evaluated for the North American Linomide Trial by automated quantitative MRI. Ann Neurol 1998; 42:A458-A459.
11. Overall JE, Doyle SR. Estimating sample sizes for repeated measurement designs. Controlled Clin Trials 1994;15:100-123.
12. Comi G, Filippi M, for the Copaxone MRI Study Group. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment. Neurology 1999;52(S2):A289. Abstract.
13. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999;353:964-969.
14. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
15. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin- echo MRI in multiple sclerosis. Neurology 1998;50:1282-1288.
16. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR 1998;19:675-683.
17. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in the monitoring of the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
18. Li DKB, Paty DW, MS/MRI Analysis Research Group and the PRISMS (prevention of relapses and disability by interferon-beta 1a subcutaneously in multiple sclerosis) Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206.
19. Miller DH, Molyneux PD, Barker GJ, et al. Effect of interferon beta-1b on MRI outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomised, double-blind, placebo-controlled trial. Ann Neurol 1999;46: 850-859.
20. Van Waesberghe JHT, Castelijns JA, Scheltens P, et al. Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. Magn Reson Imaging 1997;15:155-162.
21. O'Riordan JI, Gawne Cain M, Coles A, et al. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult Scler 1998;4:408-412.
22. Truyen L, Van Waesberghe JHTM, Van Walderveen MAA et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476.
23. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
24. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997;42:379-382.